Literature DB >> 9736574

Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.

W A Krueger1, T H Schroeder, M Hutchison, E Hoffmann, H J Dieterich, A Heininger, C Erley, A Wehrle, K Unertl.   

Abstract

The pharmacokinetics of meropenem were studied in nine anuric critically ill patients treated by continuous venovenous hemodiafiltration. Peak levels after infusion of 1,000 mg over 30 min amounted to 103.2 +/- 45.9 microgram/ml, and trough levels at 12 h were 9.6 +/- 3.8 microgram/ml. A dosage of 1,000 mg of meropenem twice a day provides plasma drug levels covering intermediately susceptible microorganisms. Further reductions of the dosage might be appropriate for highly susceptible bacteria or when renal replacement therapies with lower clearances are applied.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736574      PMCID: PMC105844     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections.

Authors:  S Mehtar; E P Dewar; D J Leaper; E W Taylor
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

2.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

3.  A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.

Authors:  H C Kelly; M Hutchison; S J Haworth
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

Review 4.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

Review 5.  Continuous arteriovenous hemofiltration in acute renal failure.

Authors:  T A Golper
Journal:  Am J Kidney Dis       Date:  1985-12       Impact factor: 8.860

6.  The disposition and metabolic fate of 14C-meropenem in man.

Authors:  M P Harrison; S J Haworth; S R Moss; D M Wilkinson; A Featherstone
Journal:  Xenobiotica       Date:  1993-11       Impact factor: 1.908

7.  Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.

Authors:  S R Norrby; P A Newell; K L Faulkner; W Lesky
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

8.  Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.

Authors:  Y J Mouton; C Beuscart
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

Review 9.  Meropenem: a microbiological overview.

Authors:  J R Edwards
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

Review 10.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

View more
  26 in total

1.  Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Heiko Hickstein; Astrid Francke; Annette Pertschy; Martin Schulz; Ralf Mundkowski; Bernd Drewelow
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

3.  Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.

Authors:  Sean K Gorman; Richard S Slavik; Stefanie Lam
Journal:  Can J Hosp Pharm       Date:  2012-05

4.  Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Authors:  Wolfgang A Krueger; Volkhard A J Kempf; Manou Peiffer; Udo Nagele; Klaus E Unertl; Torsten H Schroeder
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

5.  Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.

Authors:  I Bilgrami; J A Roberts; S C Wallis; J Thomas; J Davis; S Fowler; P B Goldrick; J Lipman
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

6.  Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Authors:  Eugenia Yeh; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

Review 7.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

8.  A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy.

Authors:  Sanjoy Ketan Paul; Jason A Roberts; Jeffrey Lipman; Renae Deans; Mayukh Samanta
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

Review 9.  Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Menino Osbert Cotta
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

10.  Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.

Authors:  Julia Langgartner; Antje Vasold; Thomas Glück; Michel Reng; Frieder Kees
Journal:  Intensive Care Med       Date:  2008-02-23       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.